Bright Peak Therapeutics Appoints John Schmid to its Board of Directors [Yahoo! Finance]
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at Johnson Rice.
Anaptys Announces Stock Repurchase Plan
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at Guggenheim.